Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2016 

 

 

AVEO Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-34655   04-3581650

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Broadway, 14th Floor

Cambridge, Massachusetts

  02142
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 588-1960

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 26, 2016, AVEO Pharmaceuticals, Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 58,181,715 shares of common stock outstanding as of March 31, 2016, the record date, 44,028,534 shares were represented at the Annual Meeting (in person or by proxy), constituting 75.67% of the outstanding shares entitled to vote. At the Annual Meeting, the Company’s stockholders voted on the following proposals:

1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2017 annual meeting of stockholders.

 

     For    Withheld    Broker Non-Votes

Mr. Michael Bailey

   18,361,503    481,744    25,185,287

Mr. Kenneth Bate

   17,050,505    1,792,742    25,185,287

Dr. Anthony Evnin

   18,329,967    513,280    25,185,287

Mr. Henri Termeer

   18,361,267    481,980    25,185,287

Dr. Robert Young

   18,366,578    476,669    25,185,287

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

 

For:

   18,201,331

Against:

   496,243

Abstain:

   145,673

Broker Non-Votes:

   25,185,287

3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2016 was ratified.

 

For:

   42,764,578

Against:

   864,714

Abstain:

   399,242

Broker Non-Votes:

   44,028,534


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AVEO Pharmaceuticals, Inc.
Date: May 31, 2016      
    By:  

/s/ Michael Bailey

      Michael Bailey
      President and Chief Executive Officer